Stimulation Tests for the Bone Marrow Neutrophil Pool in Malignancies

References

• DeVita V. T., Hubbard S. M., Longo D. L. The chemotherapy of lymphomas: looking back, moving forward—The Richard and Hinda Rosenthal Foundation award lecture. Cancer Res. 1987; 47: 5810–5824
   PubMed Web of Science ®Google Scholar
• Linch D. C., Winfield D., Goldstone A. H., Moir D., Hancock B., McMillan A., Chopra R., Milligan D., Hudson G. V. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodg-kin's disease: results of a BNLI randomised trial. Lancet 1993; 341: 1051–1054
   PubMed Web of Science ®Google Scholar
• Kotake T., Miki T., Akaza H., Kubota Y., Nishio Y., Matsumura Y., Ota K., Ogawa N. Effect of recombinant granulocyte colony-stimulating factor (rG-CSF) on chemotherapy-induced neutropenia in patients with urogenital cancer. Cancer Chemother. Pharmacol. 1991; 27: 253–257
   PubMed Web of Science ®Google Scholar
• Crawford J., Ozer H., Stoller R., Johnson D., Lyman G., Tabbara I., Kris M., Grous J., Picozzi V., Rausch G., Smith R., Gradishar W., Yahanda A., Vincent M., Stewart M., Glaspy J. Reduction by granulocyte colony-stimulating factor and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N. Engl. J. Med. 1991; 325: 164–170
   PubMed Web of Science ®Google Scholar
• Trillet-Lenoir V., Green J., Manegold C., Pawel J. V., Gatzemeier U., Lebeau B., Depierre A., Johnson P., De-Coster G., Tomati D., Ewen C. Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur. J. Cancer 1993; 29A: 319–324
   PubMed Web of Science ®Google Scholar
• Pettengell R., Gurney H., Radford J. A., Deakin D. P., James R., Wilkinson P. M., Kane K., Bentley J., Crowther D. Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: A randomized controlled trial. Blood 1992; 80: 1430–1436
   PubMed Web of Science ®Google Scholar
• Gerhartz H. H., Engelhard M., Meusers P., Brittinger G., Wilmanns W., Schlimok G., Mueller P., Huhn D., Musch R., Siegert W., Gerhartz D., Hartlapp J. H., Thiel E., Huber C., Peschl C., Spann W., Emmerich B., Schadek C., Westerhausen M., Pees H.-W., Radtke H., Engert A., Terhardt E., Schick H., Binder T., Fuchs R., Hasford J., Brandmaier R., Stern A. C., Jones T. C., Ehrlich H. J., Stein H., Parwaresch M., Tiemann M., Lennert K. Randomized, double-blind, placebo-controlled, phase III study of recombinant human granulocyte-macrophage colony-stimulating factor as adjunct to induction treatment of high-grade malignant non-Hodgkin's lymphomas. Blood 1993; 82: 2329–2339
   PubMed Web of Science ®Google Scholar
• Fleischmann J., Golde D. W., Weisbart R. H., Gasson J. C. Granulocyte-macrophage colony-stimulating factor enhances phagocytosis of bacteria by human neutrophils. Blood 1986; 68: 708–711
   PubMed Web of Science ®Google Scholar
• Nathan C. F. Respiratory burst in adherent human neutrophils: Triggering by colony-stimulating factors CSF-GM and CSF-G. Blood 1989; 73: 301–306
   PubMed Web of Science ®Google Scholar
• Peters W. P., Stuart A., Affronti M. L., Kim C. S., Coleman R. E. Neutrophil migration is defective during recombinant human granulocyte-macrophage colony-stimulating factor infusion after autologous bone marrow transplantation in humans. Blood 1988; 72: 1310–1315
   PubMed Web of Science ®Google Scholar
• Wang J. M., Chen Z. G., Colella S., Bonilla M. A., Welte K., Bordignon C., Mantovani A. Chemotactic activity of recombinant human granulocyte-colony stimulating factor. Blood 1988; 72: 1456–1460
   PubMed Web of Science ®Google Scholar
• Athens J. W., Haab O. P., Raab S. O., Mauer A. M., Ashenbrucker H., Cartwright G. E., Wintrobe M. M. The total blood circulating and marginal granulocyte pool and the granulocyte turnover rate in normal subjects. J. Clin. Invest. 1961; 40: 989–994
   PubMed Web of Science ®Google Scholar
• Cronkite E. P., Bond V. P., Fliedner T. M., Rubini J. R., Killmann S. A. Studies on the life cycle of normal and neoplastic leukocytes by labelling DNA with tritiated thymidine. IXth Int. Congress of Radiology. Urban & Schwarzenberg, Munich 1960; 894–905
   Google Scholar
• Cronkite E. P., Vincent P. C. Granulocyto-poiesis. Series Haematologica 1969; vol. II(4)3–43
   Google Scholar
• Fliedner T. M., Cronkite E. P., Robertson J. S. Granulocytopoiesis. I. Senescence and random loss of neutrophilic granulocytes in human beings. Blood 1964; 24: 402–414
   PubMed Web of Science ®Google Scholar
• Mauer A. M., Athens J. W., Ashenbrucker H., Cartwright G. E., Wintrobe M. M. Leukokinetic studies. II. A method for labeling granulocytes in vitro with radioactive diisopropylfluorophosphate DFP32. J. Clin. Invest. 1960; 39: 1481–1486
   PubMed Web of Science ®Google Scholar
• Bronchud M. H., Potter M. R., Morgenstem G., Blasco M. J., Scharffe J. H., Thatcher N., Crowther D., Souza L. M., Alton N. K., Testa N. G., Dexter T. M. In vitro and in vivo analysis of the effects of recombinant human granulocyte colony-stimulating factor in patients. Br. J. Cancer 1988; 58: 64–69
   PubMed Web of Science ®Google Scholar
• Devereux S., Linch D. C., Campos-Costa D., Spittle M. F., Jelliffe A. M. Transient leucopenia induced by granulocyte macrophage colony stimulating factor (Letter). Lancet 1987; II: 1523–1524
   Google Scholar
• Lord B. I., Bronchud M. H., Owens S., Chang J., Howell A., Souza L., Dexter T. M. The kinetics of human granulopoiesis following treatment with granulocyte colony-stimulating factor in vivo. Proc. Natl. Acad. Sci. 1989; 86: 9499–9503
   PubMed Web of Science ®Google Scholar
• Morstyn G., Campbell L., Souza L. M., Alton N. K., Keech J., Green M., Sheridan W., Metcalf D., Fox R. Effect of granulocyte colony stimulating factor on neutropenia induced by cytotoxic chemotherapy. Lancet 1988; I.: 667–672
   Web of Science ®Google Scholar
• Socinski M. A., Cannistra S. A., Sullivan R., Elias A., Amman K., Schnipper L., Griffin J. D. Granulocyte-macrophage colony-stimulating factor induces the expression of the CD1 lb surface adhesion molecule on human granulocytes in vivo. Blood 1988; 72: 691–697
   PubMed Web of Science ®Google Scholar
• Hansen P. B., Kjarsgaard E., Johnsen H. E., Gram J., Pedersen M., Nikolajsen K., Hansen N. E. Different membrane expression of CDllb and CD 14 on blood neutrophils following in vivo administration of myeloid growth factors. Br. J. Haematol. 1993; 85: 50–56
   PubMed Web of Science ®Google Scholar
• Johnsen H. E., Hansen P. B., Plesner T., Jensen L., Gaarsdal E., Andersen H., Hansen S. W., Birgens H., Jacobsen G. K., Kjairsgaard E., Hansen N. E. Increased yield of myeloid progenitor cells in bone marrow harvested for autologous transplantation by pretreatment with recombinant human granulocyte-colony stimulating factor. Bone Marrow Transplant 1992; 10: 229–234
   PubMed Web of Science ®Google Scholar
• Lord B. I., Gurney H., Chang J., Thatcher N., Crowther D., Dexter T. M. Haemopoietic cell kinetics in humans treated with rhGM-CSF. Int. J. Cancer 1992; 50: 26–31
   PubMed Web of Science ®Google Scholar
• Kappas A., Hellman L., Fukushima D. K., Gallagher T. F. The pyogenic effect of etiocholanolone. J. Clin. Endocrinol. Metab. 1957; 17: 451–453
   PubMed Web of Science ®Google Scholar
• Kimball H. R., Vogel J. M., Perry S., Wolff S. M. Quantitative aspects of pyrogenic and hematologic responses to etiocholanolone in man. J. Lab. Clin. Med. 1967; 69: 415–427
   PubMedGoogle Scholar
• Vogel J. M., Yankee R. A., Kimball H. R., Wolff S. M., Perry H. R. The effect of etiocholanolone on granulocyte kinetics. Blood 1967; 30: 474–484
   PubMed Web of Science ®Google Scholar
• Godwin H. A., Zimmerman T. S., Kimball H. R., Wolff S. M., Perry S. The effect of etiocholanolone on the entry of granulocytes into the peripheral blood. Blood 1968a; 31: 461–470
   PubMed Web of Science ®Google Scholar
• Godwin H. A., Zimmerman T. S., Kimball H. R., Wolff S. M., Perry S. Correlation of granulocyte mobilization with etiocholanolone and the subsequent development of myelosuppression in patients with acute leukemia re-cieving therapy. Blood 1968b; 31: 580–588
   PubMed Web of Science ®Google Scholar
• Vogel J. M., Kimball H. R., Wolff S. M., Perry S. Etiocholanolone in the evaluation of marrow reserves in patients receiving cytotoxic agents. Ann. Int. Med. 1967; 67: 1226–1238
   PubMed Web of Science ®Google Scholar
• Karjalainen J., Wasastjerna C. The etiocholanolone test for prediction of the leukopenic effect of cytotoxic drugs. Scand. J. Haematol. 1973; 11: 337–341
   PubMedGoogle Scholar
• Bishop C. R., Athens J. W., Boggs D. R., Warner H. R., Cartwright G. E., Wintrobe M. M. Leukokinetic studies. XIII. A non-steady-state kinetic evaluation of the mechanism of cortisone-induced granulocytosis. J. Clin. Invest. 1968; 47: 249–260
   PubMed Web of Science ®Google Scholar
• Cream J. J. Prednisolone-induced granulocytosis. Br. J. Haematol. 1968; 15: 259–267
   PubMed Web of Science ®Google Scholar
• Bishop C. R., Athens J. W., Boggs D. R., Cartwright G. E. The mechanism of Cortisol induced granulocytosis. Clin. Res. 1967; 15: 130–135
   Google Scholar
• Vincent P. C., Chanana A. D., Cronkite E. P., Joel D. D. The intravascular survival of neutrophils labeled in vivo. Blood 1974; 43: 371–377
   PubMed Web of Science ®Google Scholar
• Craddock C. G., Perry S., Ventzke L. E., Lawrence J. S. Evaluation of marrow granulocyte reserves in normal and disease states. Blood 1960; 15: 840–855
   PubMed Web of Science ®Google Scholar
• Marsh J. C., Perry S. The granulocyte response to endotoxin in patients with hematologic disorders. Blood 1964; 23: 581–599
   PubMed Web of Science ®Google Scholar
• DeConti R. C., Kaplan S. R., Calabresi P. Endotoxin stimulation in patients with lymphoma: Correlation with the myelosuppressive effects of alkylating agents. Blood 1972; 39: 602–609
   PubMed Web of Science ®Google Scholar
• Korbitz B. C., Toren F. A., Davis H. L., Ramirez G., Ansfield F. J. The Piroman test: A useful assay of bone marrow granulocyte reserves. Curr. Ther. Res. 1969; 11: 491–505
   PubMed Web of Science ®Google Scholar
• Hansen P. B., Johnsen H. E., Ralfkiaer E., Hansen N. E. Blood neutrophil increment after a single injection of rhG-CSF or rhGM-CSF correlates with marrow cellularity and may predict the grade of neutropenia after chemotherapy. Br. J. Haematol. 1993; 84: 581–585
   PubMed Web of Science ®Google Scholar
• Bierman H. R., Kelly K. H., Cordes F. L., Byron R. L., Polhemus J. A., Rappoport S. The release of leukocytes and platelets from the pulmonary circulation by epinephrine. Blood 1952; 7: 683–692
   PubMed Web of Science ®Google Scholar
• Groisser V. W., Ruberman W., Brooklyn N. Y. The hematologic response to adrenalin. J. Lab. Clin. Med. 1954; 43: 386–394
   PubMedGoogle Scholar
• Boggs D. R., Joyce R. A. The hematopoietic effects of lithium. Semin. Hematol. 1983; 20: 129–138
   PubMed Web of Science ®Google Scholar
• Rothstein G., Clarkson D. R., Larsen W., Grosser B. I., Athens J. W. Effect of lithium on neutrophil mass and production. N. Engl. J. Med. 1978; 298: 178–180
   PubMed Web of Science ®Google Scholar
• Luman G. H., Williams C. C., Preston D. The use of lithium carbonate to reduce infection and leukopenia during systemic chemotherapy. N. Engl. J. Med. 1980; 302: 257–260
   PubMed Web of Science ®Google Scholar
• Meropol N. J., Miller L. L., Korn E. L., Braitman L. E., MacDermott M. L., Schuster L. M. Severe myelosuppression resulting from concurrent administration of granulocyte colony-stimulating factor and cytotoxic chemotherapy. J. Natl. Cancer Inst. 1992; 84: 1201–1203
   PubMed Web of Science ®Google Scholar